RPG Life Sciences' API Carve-Out, PE Partnership, and Twin Acquisitions
RPG Life Sciences Ltd 路 Investor Presentation 路 03 Sept 2026, 4:04 am
RPG Life Sciences' API Carve-Out, PE Partnership, and Twin Acquisitions RPG Life Sciences subsidiarized its API business into RPG Active Pharma (RPGAP). PE firm InvAscent is acquiring a 40% stake in RPGAP for ~INR 243.33 Cr. Concurrently, RPGAP announced two acquisitions: 100% of Actis Generics for ~INR 80 Cr and Raghava Life Sciences via a ~INR 135 Cr slump sale. These strategic transactions quadruple RPGAP's installed capacity across Vizag and Hyderabad, add ~INR 200 Cr in revenue potential, and strengthen its high-margin niche API portfolio while maintaining a zero-debt balance sheet.
Original exchange filing (PDF)
More announcements from RPG Life Sciences Ltd
- Earning call Transcript 路 05 Nov 2026
- Audio Recording of Q2FY27 Results Earnings Call held on October 30, 2026 路 31 Oct 2026
- Investor Presentation 路 30 Oct 2026
- Amendment to Policy on Related Party Transactions 路 30 Oct 2026
- Press Release 路 30 Oct 2026
- Outcome of Board Meeting held on October 29, 2026. 路 30 Oct 2026
- Financial Result for the quarter ended September 30, 2026 路 30 Oct 2026
- Outcome of Board Meeting 路 30 Oct 2026
